


Claims

1. A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,




5 wherein

R¹ is hydrogen,


R² is hydrogen or C1-20-alkyl,

R³ is hydrogen, C1-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, C1-20-alkoxy, or a group of formula -W-R⁸.

10 R^{3a} is hydrogen, C1-20-alkyl or a group of formula:



or NR³R^{3a} is a group of formula



R⁴ is hydrogen,

15 R⁵ is hydrogen; nitro; halogen; azido; cyano; -S-C1-4-alkyl; -SO-C1-4-alkyl; -SO₂-C1-4-alkyl; -SONH₂; C1-20-alkyl unsubstituted or substituted by halogen; or C1-20-alkoxy unsubstituted or substituted by halogen.

R⁶ is hydrogen, C1-20-alkyl or halogen,

R⁷ is hydrogen, C1-20-alkyl or halogen,

20 W is C1-12-alkylene, -NH- or -NHC(=O)-,

X is O, S or NH,

Y is O, S, -CR¹²R¹³-, -NR¹⁴- or -C(=O)-,

R⁸ is aryl or heterocycle,

R⁹, R¹⁰, R^{10a} and R¹¹ are independently selected from hydrogen, C1-4-alkyl,

25 halogen, hydroxy or methoxycarbonyl,

or R¹⁰ and R^{10a} together form a C3-6-alkylene,

R¹² is hydrogen, C1-4-alkyl, halogen or hydroxy,

R¹³ is hydrogen,

or $CR^{12}R^{13}$ is dioxolanyl,

R^{14} is aryl, heterocycle or a group of formula $-V-R^{15}$,

V is C1-12-alkylene,

R^{15} is aryl or heterocycle,


5 m is 1 to 4,

n is 0 or 1,

and at least one of R^5 , R^6 or R^7 is different from hydrogen when R^2 is hydrogen,

R^3 is H or 2,6-diisopropylphenyl, and R^{3a} is H.

10 2. A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,



wherein


R^1 is hydrogen,

15 R^2 is hydrogen or C1-4-alkyl,

R^3 is hydrogen; C1-6-alkyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, hydroxy, alkoxy, alkoxycarbonyl or alkylamino; C5-7-cycloalkyl; (hydroxymethyl)cyclohexenyl; phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, C1-4-alkyl, hydroxy, methoxy, nitro,

20 methylsulfonyl, trifluoromethylthio or pyridinylalkyl; pyridinyl unsubstituted or substituted by methoxy; triazolyl; C1-4-alkoxy; or a group of formula $-W-R^8$,


R^{3a} is hydrogen, C1-4-alkyl or a group of formula



or NR^3R^{3a} is piperidinyl unsubstituted or substituted by hydroxy;

25 thiomorpholinyl; thiazolidinyl unsubstituted or substituted by C1-4-

alkoxycarbonyl; 2,5-dihydro-1H-pyrrol-1-yl; 1,4-dioxa-8-azaspiro[4.5]dec-8-yl; 4-oxooctahydro-1(2H)-quinolinyl; or a group of formula



30 R^4 is hydrogen,

R⁵ is hydrogen; nitro; halogen; C1-4-alkyl, unsubstituted or substituted by halogen; or C1-4-alkoxy unsubstituted or substituted by halogen,

R⁶ is hydrogen, C1-6-alkyl or halogen,

R⁷ is hydrogen, methyl or halogen,

5 W is C1-4-alkylene unsubstituted or substituted by halogen, hydroxy, C1-4-alkyl or alkoxy; -NH-; or -NHC(=O)-,

R⁸ is phenyl unsubstituted or substituted by 1 to 5 substituents selected from halogen, C1-4-alkyl, hydroxy, methoxy, nitro, methylsulfonyl or trifluoromethylthio; furyl unsubstituted or substituted by methyl; pyrazolyl;

10 pyridinyl; morpholinyl; tetrahydrobenzazocinyl; piperidinyl unsubstituted or substituted by methyl; dihydroisochromenyl or dihydroimidazolyl,

R¹⁴ is pyridinyl; phenyl unsubstituted or substituted by halogen, hydroxy, C1-4-alkyl; or a group of formula -V-R¹⁵,

V is unsubstituted C1-4-alkylene,


15 R¹⁵ is phenyl or morpholinyl,

m is 1 to 4,

and at least one of R⁵, R⁶ or R⁷ is different from hydrogen when R² is hydrogen,

R³ is H or 2,6-diisopropylphenyl, and R^{3a} is H.

20 3. A compound having the formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,



wherein

R¹ is hydrogen,

25 R² is hydrogen, methyl or ethyl,

R³ is hydrogen, n-butyl, cycloheptyl, 2-fluoroethyl, 3-hydroxypropyl, 3-hydroxy-

2,2-dimethylpropyl, 1-(hydroxymethyl)propyl, 3,3,3-trifluoro-2-hydroxypropyl, 3-

ethoxypropyl, 2-ethoxy-2-oxoethyl, 3-(dimethylamino)propyl, 6-

(hydroxymethyl)cyclohex-3-en-1-yl, 3-hydroxyphenyl, 3-fluorophenyl, 3-(2-pyridin-

30 2-ylethyl)phenyl, 3,4-dimethylphenyl, 4-tert-butylphenyl, benzyl, 4-hydroxy-3-

methoxybenzyl, 4-methylsulfonylbenzyl, 2-nitrobenzyl, 2-chloro-6-fluorobenzyl, 2-

[(trifluoromethyl)thio]benzyl, 2-hydroxy-2-phenylethyl, 2-(3,4-

dimethoxyphenyl)ethyl, 2-(2-chlorophenyl)ethyl, 2-(4-methylphenyl)ethyl, (4-bromophenyl)amino, pyridin-3-yl, 6-methoxypyridin-3-yl, 4H-1,2,4-triazol-3-yl, pyridin-4-ylmethyl, (5-methyl-2-furyl)methyl, 3-(1H-pyrazol-1-yl)propyl, 2-morpholin-4-ylethyl, 2-((3,4,5,6-tetrahydro-1-benzazocin-1(2H)-yl)propyl, 2-(2-

5 methylpiperidin-1-yl)ethyl, 3,4-dihydro-1H-isochromen-1-ylmethyl, methoxy, (4-pyridinylcarbonyl)amino or 4,5-dihydro-1H-imidazol-2-ylamino,

R^{3a} is hydrogen, methyl or tetrahydrofuran-2-ylmethyl,

or NR³R^{3a} 4-pyridin-2-ylpiperazin-1-yl, 4-(3-methylphenyl)piperazin-1-yl, 4-(4-hydroxyphenyl)piperazin-1-yl, 4-(2-phenylethyl)piperazin-1-yl, 4-(2-morpholin-4-

10 ylethyl)piperazin-1-yl, 3-hydroxypiperidin-1-yl, thiomorpholin-4-yl, 4-methoxycarbonyl-1,3-thiazolidin-3-yl, 2,5-dihydro-1H-pyrrol-1-yl, 1,4-dioxa-8-azaspiro[4.5]dec-8-yl or 4-oxooctahydro-1(2H)-quinolinyl,

R⁴ is hydrogen,

R⁵ is hydrogen, methyl, ethyl, trifluoromethyl, trifluoromethoxy, n-propyl,

15 isopropyl, nitro or halogen,

R⁶ is hydrogen, methyl or Cl,

R⁷ is hydrogen, methyl, Br, F or Cl,

and at least one of R⁵, R⁶ or R⁷ is different from hydrogen when R² is hydrogen,

R³ is H or 2,6-diisopropylphenyl, and R^{3a} is H.

20

4. A compound according to any of the claims 1 to 3 wherein R² is hydrogen or methyl.

5. A compound according to any of the preceding claims wherein R³ is hydrogen.

25

6. A compound according to any of the preceding claims wherein R^{3a} is hydrogen.

7. A compound according to any of the preceding claims wherein R⁵ is halogen or trifluoromethyl.

30

8. A compound according to any of the preceding claims wherein R⁶ is hydrogen.

9. A compound according to any of the preceding claims wherein R⁷ is hydrogen, Br or F.

35

10. A compound according to any of the preceding claims wherein R² is C1-20-alkyl and the carbon atom to which R² is attached is in the "S"-configuration.

11. A compound selected from 2-(5-*ido*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(5,7-*dibromo*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(5-*nitro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(5-*methyl*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)propanamide; (2*R*)-2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)propanamide; (2*S*)-2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)propanamide; 2-[2-*oxo*-5-(trifluoromethoxy)-2,3-dihydro-1*H*-indol-1-*yl*]acetamide; 2-(5-*isopropyl*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(5-*ethyl*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(5-*fluoro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(5,7-*dimethyl*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(5-*bromo*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(2-*oxo*-5-*propyl*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-[2-*oxo*-5-(trifluoromethyl)-2,3-dihydro-1*H*-indol-1-*yl*]acetamide; 2-(5,6-*dimethyl*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(7-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(6-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)butanamide; (+)-2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)butanamide; (-)-2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)propanamide; (+)-2-(5-*methyl*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)propanamide; (-)-2-(5-*methyl*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)propanamide; 2-(5-*bromo*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)propanamide; (-)-2-(5-*bromo*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)propanamide; (+)-2-(5-*bromo*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)propanamide; 2-(5-*chloro*-7-*fluoro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)acetamide; 2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)-N-(3-*hydroxyphenyl*)acetamide; 2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)-N-(3-*fluorophenyl*)acetamide; 2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)-N-[3-(2-*pyridin-2-ylethyl*)phenyl]acetamide; 2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)-N-[6-(*hydroxymethyl*)cyclohex-3-en-1-*yl*]acetamide; 5-*chloro*-1-[2-*oxo*-2-(4-*pyridin-2-yl*piperazin-1-*yl*)ethyl]-1,3-dihydro-2*H*-indol-2-one; 5-*chloro*-1-[2-[4-(3-*methylphenyl*)piperazin-1-*yl*]-2-*oxoethyl*]-1,3-dihydro-2*H*-indol-2-one; 2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)-N-(4-*hydroxy*-3-*methoxybenzyl*)acetamide; 2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)-N-(*pyridin-4-ylmethyl*)-N-(*tetrahydrofuran-2-ylmethyl*)acetamide; 5-*chloro*-1-[2-(3-*hydroxypiperidin-1-yl*)-2-*oxoethyl*]-1,3-dihydro-2*H*-indol-2-one; 2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)-N'-isonicotinoylacetohydrazide; 5-*chloro*-1-(2-*oxo*-2-thiomorpholin-4-*ylethyl*)-1,3-dihydro-2*H*-indol-2-one; 2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)-N-(4*H*-1,2,4-triazol-3-*yl*)acetamide; 2-(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)-N-[4-(*methylsulfonyl*)benzyl]acetamide; 1-[(5-*chloro*-2-*oxo*-2,3-dihydro-1*H*-indol-1-*yl*)-N-[4-(*methylsulfonyl*)benzyl]acetamide];


2,3-dihydro-1H-indol-1-yl)acetyl]octahydroquinolin-4(1H)-one; N'-(4-bromophenyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetohydrazide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(6-methoxypyridin-3-yl)acetamide; N-butyl-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxypropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[3-(dimethylamino)propyl]acetamide; 5-chloro-1-[2-oxo-2-[4-(2-phenylethyl)piperazin-1-yl]ethyl]-1,3-dihydro-2H-indol-2-one; ethyl {[[(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetyl]amino]acetate; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-ethoxypropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-fluoroethyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-methoxy-N-methylacetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,4-dimethylphenyl)acetamide; N-(4-tert-butylphenyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3-hydroxy-2,2-dimethylpropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[1-(hydroxymethyl)propyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,3,3-trifluoro-2-hydroxypropyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-hydroxy-2-phenylethyl)acetamide; 5-chloro-1-[2-[4-(4-hydroxyphenyl)piperazin-1-yl]-2-oxoethyl]-1,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(pyridin-4-ylmethyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[(5-methyl-2-furyl)methyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[3-(1H-pyrazol-1-yl)propyl]acetamide; methyl 3-[(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetyl]-1,3-thiazolidine-4-carboxylate; 5-chloro-1-[2-(2,5-dihydro-1H-pyrrol-1-yl)-2-oxoethyl]-1,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N'-(4,5-dihydro-1H-imidazol-2-yl)acetohydrazide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(2-chlorophenyl)ethyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(4-methylphenyl)ethyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-morpholin-4-ylethyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(3,4,5,6-tetrahydro-1-benzazocin-1(2H)-yl)propyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-(2-methylpiperidin-1-yl)ethyl]acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(2-nitrobenzyl)acetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-(3,4-dihydro-1H-isochromen-1-ylmethyl)acetamide; N-(2-chloro-6-fluorobenzyl)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; N-benzyl-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-methylacetamide; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-[2-[(trifluoromethyl)thio]benzyl]acetamide; 5-chloro-1-[2-(1,4-dioxa-8-

azaspiro[4.5]dec-8-yl]-2-oxoethyl]-1,3-dihydro-2H-indol-2-one; 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-cycloheptylacetamide; 5-chloro-1-[2-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]-2-oxoethyl]-1,3-dihydro-2H-indol-2-one; and 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)-N-pyridin-3-ylacetamide.



5

12. A compound selected from 2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide and (2S)-2-(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)propanamide.

13. A compound having the formula II or stereoisomeric forms thereof,



10 wherein

 R^1 is hydrogen, R^2 is hydrogen or C1-20-alkyl, R^3 is hydrogen, C1-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, C1-20-alkoxy, or a group of formula $-W-R^8$.15 R^{3a} is hydrogen, C1-20-alkyl or a group of formula:or NR^3R^{3a} is a group of formula20 R^4 is hydrogen, R^5 is hydrogen; nitro; halogen; azido; cyano; $-S-C1-4-alkyl$; $-SO-C1-4-alkyl$; $-SO_2-C1-4-alkyl$; $-SONH_2$; C1-20-alkyl unsubstituted or substituted by halogen; or C1-20-alkoxy unsubstituted or substituted by halogen, R^6 is hydrogen, C1-20-alkyl or halogen, R^7 is hydrogen, C1-20-alkyl or halogen,25 W is C1-12-alkylene, $-NH-$ or $-NHC(=O)-$, X is O, S or NH, Y is O, S, $-CR^{12}R^{13}-$, $-NR^{14}-$ or $-C(=O)-$, R^8 is aryl or heterocycle,

R⁹, R¹⁰, R^{10a} and R¹¹ are independently selected from hydrogen, C1-4-alkyl, halogen, hydroxy or methoxycarbonyl, or R¹⁰ and R^{10a} together form a C3-6-alkylene, R¹² is hydrogen, C1-4-alkyl, halogen or hydroxy.


5 R¹³ is hydrogen, or CR¹²R¹³ is dioxolanyl, R¹⁴ is aryl, heterocycle or a group of formula -V-R¹⁵,

V is C1-12-alkylene,

R¹⁵ is aryl or heterocycle,

10 m is 1 to 4, n is 0 or 1, and at least one of R⁵, R⁶ or R⁷ is different from hydrogen when R² is hydrogen, R³ is H or 2,6-diisopropylphenyl, and R^{3a} is H.

15 14. A compound having the formula III or stereoisomeric forms thereof,



wherein

R⁴ is hydrogen,

R⁵ is hydrogen; nitro; azido; cyano; -S-C1-4-alkyl; -SO-C1-4-alkyl;

20 -SO₂-C1-4-alkyl; -SONH₂; C1-20-alkyl unsubstituted or substituted by halogen; or C1-20-alkoxy unsubstituted or substituted by halogen,


R⁶ is hydrogen, C1-20-alkyl or halogen,

R⁷ is hydrogen, C1-20-alkyl or halogen,

and at least one of R⁵, R⁶ or R⁷ is different from hydrogen.

25

15. A compound having the formula VI or stereoisomeric forms thereof,




wherein

R¹ is hydrogen,

R^2 is hydrogen or C1-20-alkyl,


R^3 is hydrogen, C1-20-alkyl, C4-8-cycloalkyl, C5-8-cycloalkenyl, aryl, aromatic or non aromatic heterocycle, C1-20-alkoxy, or a group of formula -W-R⁸.

R^{3a} is hydrogen, C1-20-alkyl or a group of formula:



5

or NR³R^{3a} is a group of formula:



R^4 is hydrogen,

R^5 is hydrogen; halogen; azido; cyano; -S-C1-4-alkyl; -SO-C1-4-alkyl;

10 -SO₂-C1-4-alkyl; -SONH₂; or C1-20-alkyl unsubstituted or substituted by halogen,

R^6 is hydrogen, C1-20-alkyl or halogen,

R^7 is hydrogen, C2-20-alkyl or halogen,

W is C1-12-alkylene, -NH- or -NHC(=O)-,

15 X is O, S or NH,

Y is O, S, -CR¹²R¹³-, -NR¹⁴- or -C(=O)-,

R^8 is aryl or heterocycle,

R^9 , R^{10} , R^{10a} and R^{11} are independently selected from hydrogen, C1-4-alkyl,

halogen, hydroxy or methoxycarbonyl,

20 or R^{10} and R^{10a} together form a C3-6-alkylene,

R^{12} is hydrogen, C1-4-alkyl, halogen or hydroxy,

R^{13} is hydrogen,

or CR¹²R¹³ is dioxolanyl,

R^{14} is aryl, heterocycle or a group of formula -V-R¹⁵,

25 V is C1-12-alkylene,

R^{15} is aryl or heterocycle,


m is 1 to 4,

n is 0 or 1,

and at least one of R^5 , R^6 or R^7 is different from hydrogen when R^2 is hydrogen,

30 R^3 is H or 2,6-diisopropylphenyl, and R^{3a} is H.

16. A compound having the formula IX or stereoisomeric forms thereof,



wherein

R¹ is hydrogen,

R² is hydrogen or C1-20-alkyl,

5 R⁴ is hydrogen,

R⁵ is hydrogen; nitro; azido; cyano; -S-C1-4-alkyl; -SO-C1-4-alkyl;

-SO₂-C1-4-alkyl; -SONH₂; halogen; C1-20-alkyl unsubstituted or substituted by halogen; or C1-20-alkoxy unsubstituted or substituted by halogen,

R⁶ is hydrogen, C1-20-alkyl or halogen,

10 R⁷ is hydrogen, C1-20-alkyl or halogen,

and at least one of R⁵, R⁶ or R⁷ is different from hydrogen when R² is hydrogen,

R³ is H or 2,6-diisopropylphenyl, and R^{3a} is H.

17. A compound which is selected from the group consisting of:

15 2-(5'-methyl-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide;

2-[2'-oxo-5'-[(trifluoromethyl)oxy]spiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl]acetamide;

2-[5'-(1-methylethyl)-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl]acetamide;

2-(5'-ethyl-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide;

20 2-(5'-fluoro-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide;

2-(5',7'-dimethyl-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide; 2-(2'-oxo-5'-propylspiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide;

2-[2'-oxo-5'-(trifluoromethyl)spiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl]acetamide;

2-(5',6'-dimethyl-2'-oxospiro[1,3-dithiolane-2,3'-indol]-1'(2'H)-yl)acetamide;

25 5'-methylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;

5'-[(trifluoromethyl)oxy]spiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;

5'-(1-methylethyl)spiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;

5'-ethylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;

5'-fluorospiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;

30 5',7'-dimethylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;

5'-propylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;

5'-(trifluoromethyl)spiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;

5',6'-dimethylspiro[1,3-dithiolane-2,3'-indol]-2'(1'H)-one;

2-(5-chloro-1H-indol-1-yl)propanamide;
2-(7-chloro-1H-indol-1-yl)acetamide;
2-(6-chloro-1H-indol-1-yl)acetamide;
2-(5-chloro-1H-indol-1-yl)butanamide;
5 2-(5-methyl-1H-indol-1-yl)propanamide;
2-(5-bromo-1H-indol-1-yl)propanamide;
2-(7-fluoro-1H-indol-1-yl)acetamide;
2-(5-bromo-1H-indol-1-yl)acetamide;
2-(5-fluoro-1H-indol-1-yl)acetamide;
10 2-(5-chloro-1H-indol-1-yl)acetamide;
(5-chloro-2-oxo-2,3-dihydro-1H-indol-1-yl)acetic acid.

18. A pharmaceutical composition comprising an effective amount of a compound
according to any of claims 1 to 12 in combination with a pharmaceutically
15 acceptable diluent or carrier.

19. A method for treating epilepsy, epileptogenesis, seizure disorders, convulsions,
Parkinson's disease, dyskinesia induced by dopamine replacement therapy, tardive
20 dyskinesia induced by administration of neuroleptic drugs, Huntington Chorea,
and other neurological disorders including bipolar disorders, mania, depression,
anxiety, attention deficit hyperactivity disorder (ADHD), migraine, trigeminal and
other neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac
arrhythmia, myotonia, cocaine abuse, stroke, myoclonus, tremor, essential tremor,
simple or complex tics, Tourette syndrome, restless leg syndrome and other
25 movement disorders, neonatal cerebral haemorrhage, amyotrophic lateral
sclerosis, spasticity and degenerative diseases, bronchial asthma, asthmatic status
and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and
bronchospastic syndromes as well as allergic and vasomotor rhinitis and
rhinoconjunctivitis, in a mammal in need of such treatment, comprising
30 administering a therapeutic dose of at least one compound according to any of
claims 1-12 or a pharmaceutical composition according to claim 18.

20. A compound according to any of claims 1-12 or a pharmaceutical composition
according to claim 18 for use as a medicament.

35 21. Use of a compound according to any of claims 1-12 or of a pharmaceutical
composition according to claim 18 for the manufacture of a medicament for the

treatment of epilepsy, epileptogenesis, seizure disorders, convulsions, Parkinson's disease, dyskinesia induced by dopamine replacement therapy, tardive dyskinesia induced by administration of neuroleptic drugs, Huntington Chorea, and other neurological disorders including bipolar disorders, mania, depression, anxiety, 5 attention deficit hyperactivity disorder (ADHD), migraine, trigeminal and other neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse, stroke, myoclonus, tremor, essential tremor, simple or complex tics, Tourette syndrome, restless leg syndrome and other movement disorders, neonatal cerebral haemorrhage, amyotrophic lateral sclerosis, spasticity and degenerative diseases, bronchial asthma, asthmatic status and allergic 10 bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctivitis.